Eli Lilly unveils new data from atopic dermatitis therapy trials

Eli Lilly and Company has reported new secondary data from the Phase III trials investigating lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (AD), commonly known as eczema.

The results were obtained from the ADvocate 1 and ADvocate 2 as well as the ADhere studies.